Search

Your search keyword '"Kümmerle T"' showing total 95 results

Search Constraints

Start Over You searched for: Author "Kümmerle T" Remove constraint Author: "Kümmerle T"
95 results on '"Kümmerle T"'

Search Results

1. Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the cologne-bonn cohort

2. Trade-offs between carbon stocks and biodiversity in European temperate forests

Catalog

Books, media, physical & digital resources

4. Middle-range theories of land system change

16. Predictors of serofast state after treatment for early syphilis in HIV‐infected patients

17. Predictors of serofast state after treatment for early syphilis in HIV‐infected patients.

19. Tollwut-Impfung: wann und wie?

20. Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany

21. PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis

22. Syphilis in HIV infected patients

23. Todesursachen von HIV-Patienten

24. The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline

26. Clinical and epidemiological characteristics of patients with early syphilis from three academic centres in Poland, Germany and Ireland: initial findings from the POETS study

27. Phylogenetische Analyse akuter HCV Genotyp 4 Infektionen bei HIV-positiven Männern, die Sex mit Männern (MSM) haben

28. Zusammenhang zwischen einer Hepatitis C-Koinfektion und dem virologischen Ansprechen gegenüber einer Darunavir/Ritonavir (DRV/r)-Monotherapie bei Patienten mit einer Viruslast <50 Kopien/ml in der MONET-Studie

29. Syphilis bei HIV-infizierten Patienten

30. Causes of death in HIV infected patients

31. Causes of death in HIV-infected patients from the Cologne–Bonn cohort

35. Dynamics and durability of HIV-1 neutralization are determined by viral replication.

36. Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.

37. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.

38. Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes.

39. Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance.

40. Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study.

41. Combination therapy with anti-HIV-1 antibodies maintains viral suppression.

42. Prevalence of asymptomatic sexually transmitted infections in HIV-positive men who have sex with men in Germany: results of a multicentre cross-sectional study.

43. Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study.

44. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.

45. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

46. [Preexposure prophylaxis for HIV infection--current data and recommendations].

47. Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human immunodeficiency virus-positive men who have sex with men in Germany.

48. Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection.

49. [New antiretroviral drug classes in HIV therapy].

50. Anidulafungin--state of affairs from a clinical perspective.